Baxalta to Shire: We’re young, we’re just starting to grow, and we’re rejecting your buyout offer

Carly Helfand

On Tuesday, went public with a $ 30 billion bid for that had already been rejected once. And the second time around, had the same answer: It's not happening.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS